Frustrated by information silos hindering your early-stage drug discovery? Join us for this FREE one-day scientific conference on September 25th and unlock the potential of your research. Why Attend ChemTalks? ✔ Free access to cutting-edge knowledge: Gain valuable industry insights and learn the latest advancements in drug discovery. ✔ Bridge the gap, foster collaboration: Discover strategies to break down information barriers and work seamlessly with collaborators. ✔ Be the first to know: Stay ahead of the curve with exclusive access to Chemaxon's exciting new product roadmap. ✔ Expert advice: Get personalized guidance from renowned scientists and product managers. ✔ Actionable takeaways: Implement practical strategies to accelerate your research immediately. Don't miss this free opportunity! Register now and secure your spot: https://lnkd.in/gPPX5dYU #ChemTalks #DrugDiscovery #Breakthroughs #Collaboration #Innovation #Switzerland

#GeneChat - Be sure to check out these FREE CEU opportunities coming up soon. Our linktree below contains information on these events as well as registration links. https://hubs.li/Q02h4NDZ0 #GeneticCounseling #PrecisionMedicine

👨🔬 Bionow – Business Pitching @ Sci-Tech Daresbury 👩🔬 Yesterday, Russell Oakley spoke at the Bionow Business Pitching event, co-hosted by Sci-Tech Daresbury and STFC. It was interesting to listen to the insights shared by the speakers on the current Life Science and Biomedical landscape, and engaging in discussions with fellow attendees. Thank you to everyone who came for a chat, it was lovely to meet you all. #Bionow #Pitching #Networking #Biomedical #BusinessDevelopment #JobHunt #JobHunting #JobSearch #NewJob #NewJobAlert #NewJobOpportunity #Jobs #Recruitment #Recruiting #LifeScienceJobs #ScienceJobs #ChemicalJobs #BioTechJobs #ManufacturingJobs #ResearchAndDevelopmentJobs #PharmaJobs #ClinicalJobs #ClinicalResearchJobs

🚀 Showcase Alert! September 12 at 11:30AM, Tezcat Biosciences will be presenting at LSX World Congress on the Biotech Stage! 🚀 Craig Ramirez, Ph.D. will be discussing Tezcat’s cutting-edge receptor-independent drug delivery technology, specifically targeting mutant RAS solid tumors and myeloma. Tezcat’s lead asset, TZT-102, is a revolutionary protein-drug conjugate with a novel mechanism of action. Unlike traditional therapies, TZT-102 tackles mutant RAS cancers by addressing the metabolic and phenotypic effects of mutant RAS signaling, offering a broader impact across all RAS cancers. It's designed to be resistant to drug resistance and boasts a superior therapeutic index compared to FDA-approved antibody-drug conjugates. This breakthrough offers new hope for adult patients facing these challenging conditions. Don’t miss this opportunity to learn about Tezcat's game-changing innovations in oncology! #LSXWorldCongress #PrecisionMedicine #Oncology #Biotech #DrugDevelopment #LSXUSA

Details of The Labour Party life science plan are emerging...what jumps out to LifeArc? 1/6 - Make life science a priority for DHSC 🏥 LifeArc drives basic science towards patients. Coordination between science and healthcare is vital - inc in Government. Peter Kyle Wes Streeting MP 2/6 Increase uni spinouts 🎓 🤝 LifeArc shared expertise with the recent review of spinouts, and we're supporting next steps. We're keen to ensure future initiatives reflect the needs of all the players involved, and crucially helps more health innovations reach patients faster. 3/6 Increase 'access to finance' 💷 The easier and more attractive we make it for life science companies to start, scale and stay in the UK, the better chance we have of improving patients’ lives with new innovations and maintaining the UK’s leading role in life sciences. LifeArc was active in shaping the Mansion House compact agreed by the current Government. We'll work with the next Government – whoever they are – to ensure the Compact boosts UK companies. The life sciences industry needs to demonstrate its strengths as an attractive investment – an area where LifeArc Ventures plays a key role. 4/6 Maintain R&D tax credits, review them, maintain patent box 💡 These schemes make it less expensive to do life science research in the UK - especially for the small innovative companies we work with through LifeArc Ventures. Labour saying they'll prioritise life sciences in their review of credits - great to see, given life science SMEs are uniquely dependent on them for extensive periods of 'risky' R&D. 5/6 set out key technologies for the UK to lead, including (maybe) cell and gene therapies (CGT) 🔬 CGT is very exciting and we published on the skills the UK needs to keep them accelerating ( https://lnkd.in/enwaApjq ). It's important the next Government - whoever they are - keeps this sector growing. 6/6 Much more (regulation, planning reform, skills, NHS trials, trade strategy) 🏗 LifeArc is active in all these areas and look forward to sharing 25yrs+ expertise to help inform decisions to support UK life sciences and drive more innovative health research to patients.

It is an incredibly exciting time for the life sciences ecosystem here in Massachusetts. In the biotech hub of Boston and across the Commonwealth, we are seeing continued growth. But with that growth, we also see numerous challenges, including federal regulation and competition from other states and countries, that require us to think ahead and prepare for the future. Today, MassBio released its Vision 2030 strategic roadmap outlining how we will advocate for policies that ensure access and opportunity for all patients and communities, support incentives that drive scientific innovation, and champion a vision for a more equitable healthcare system. In my role as Board Chair of MassBio, I am proud of how Vision 2030 positions us to drive the future of life sciences innovation in Massachusetts for years to come, working in collaboration with our members, our state government, and our communities. As we look toward 2030, we want Massachusetts to be recognized not only for the advancements we pioneer in science and health but also for the opportunities we have created for all.   Read the plan here: https://lnkd.in/eXQVpwhk   #MassBioVision2030 #PatientDriven  

Silence the Silos. Spark the Cures. Join ChemTalks! Imagine a world where life-saving treatments reach patients sooner. A world where communication flows freely, accelerating scientific breakthroughs. This FREE 1-day event tackles the frustration of siloed information in drug discovery. Hear renowned experts share how technology can unlock hidden connections and fast-track your research. Join the ChemTalks revolution! Together, let's bridge the gaps and accelerate cures for a healthier future. Register Now! https://lnkd.in/gPPX5dYU #ChemTalks #DrugDiscovery #Breakthroughs #Cures

Great insights from the Happy Hour organized by Biospring Partners and Vive Collective! As we reach the midpoint of 2024, the life sciences industry continues to experience the transformative power of #ArtificialIntelligence (#AI). Here’s a snapshot of the latest 🔥 hot and ❄ cold trends: 🔥 Trends: #AI-Driven Insights: From genomics to clinical trials, AI is reshaping our understanding and process huge volume of data that previously cannot be processed by only human intelligence and labor. ⏳ Faster, more comprehensive and global competitive landscape 💹 Faster, cheaper and better clinical trial design built by prior success ✅ Faster FDA clearance/approval 💰 Clear ROI has shown from our early adopters. #LLM (large language model)/ #GenerativeAI for drug discovery #Precisionmedicine/medical product powered by #AI ❄️ Cold Challenges: Lack of Hybrid Human Power: there seems to be parallel universes for life science and AI people. Our experience from the frontline is that senior leaders need to understand the roadmap to success and AI strategy, mid-level managers need to have a playbook to shape behavior change, task force needs clear communication and change management to understand, learn and advocate for use cases by AI. It is a learning journey and it will be messy. Ethical and Regulatory Concerns: a lot of life science companies are still learning to come up with AI policy internally and struggle to regulate employee behaviors. Data Quality and Integration: life science industry requires high fidelity data, hence vertical AI with life science specific data, know-how and empathy of workflow will thrive. General AI that can create a new image or write an email cannot fit the high bar of life science industry and may create the wrong first impression for life science knowledge workers to discourage them to try AI. What's your opinion? Shoutout to Poorya Sabounchi Binbin Chen, MD, PhD Jennifer Lum Kathy Ku Ryan Witt and all the amazing founders and investors to accelerate innovation in life science by the power of AI. #SaaS #B2B #biopharma #medicaldevices #ai #artificialintelligence #machinelearning #genAI #generativeai https://lnkd.in/gZ2mHwEd

Last week, we were joined by Enveda Biosciences' Director of Operations, Joel Basken, and Nicolette Surges, their Lab Manager, to talk about the importance of a supportive and integrated tech stack for a growing lab. 💻 🌱 🔬 If you missed our webinar, watch the recording to hear real-life stories and get actionable tips on: - How to recognize triggers telling you it’s time to level up your tech solution. - How to avoid costly mistakes when your early-stage lab starts to grow. - How to build a mature ecosystem of tech tools that will support your lab's growth rather than hinder it. The on-demand webinar is available now: https://lnkd.in/e4dMGeWH #ZAGENOwebinar #techstack #labsupplies #lifescience #biotech #techtips

BIO's new Early-Stage Resource Hub is perfect for early-stage biotech companies to:  ✅ Cost-Saving Programs: Access and get more information about the BIO Business Solutions® cost-saving programs designed to help your company navigate financial challenges and optimize resources. ✅ Educational Resources: Gain insights from industry experts on a variety of topics by viewing past educational webinars and a growing digital library of resources covering a wide range of topics relevant to early-stage biotech companies. ✅ Stay Up-to-Date: Stay informed about the latest BIO events, webinars, and opportunities to connect with potential partners and investors. Explore Now: https://lnkd.in/esxuv7dM